Design of a dual ERK5 kinase activation and autophosphorylation inhibitor to block cancer stem cell activity

Samanth R Kedika1, Satya P Shukla1, D Gomika Udugamasooriya2

  • 1Department of Pharmacological & Pharmaceutical Sciences, University of Houston, 4849 Calhoun Rd, Health Building 2, Room 7033, Houston, TX 77204-5037, USA.

Insights

We developed a novel dual inhibitor targeting ERK5 kinase, crucial for cancer stem cell (CSC) survival and drug resistance. This compound simultaneously blocks ERK5 activation and its ATP-binding site, offering a new strategy against cancer progression.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • ERK5 kinase signaling is increasingly recognized for its role in cancer stem cell (CSC) tumorigenicity, metastasis, and drug resistance.
  • Conventional ATP-binding site inhibitors for ERK5 have shown limited anti-cancer efficacy due to complex activation pathways.
  • Targeting ERK5 activation mechanisms is crucial for developing effective anti-CSC therapies.

Purpose of the Study:

  • To design and characterize the first dual-acting inhibitor targeting both ERK5 activation and its ATP-binding site.
  • To investigate the compound's ability to disrupt ERK5 kinase activity through two distinct mechanisms simultaneously.
  • To evaluate the efficacy of this dual inhibitor against key cancer stem cell functions.

Main Methods:

  • Design of a novel hetero-bivalent inhibitor targeting ERK5.
  • Utilized two independent assay systems to confirm dual inhibition of ERK5 activation and ATP-binding.
  • Assessed the compound's impact on CSC proliferation, colony formation, and migration.

Main Results:

  • Successfully designed a single compound that acts as a dual inhibitor of ERK5.
  • Demonstrated simultaneous blockade of the ERK5 activator binding site and the ATP-binding pocket.
  • The dual inhibitor significantly inhibited CSC colony formation, proliferation, and migration.

Conclusions:

  • A novel dual-acting ERK5 inhibitor has been developed, targeting key CSC pathways.
  • This compound effectively disrupts both ERK5 activation and kinase activity.
  • The findings present a promising new therapeutic strategy for combating cancer stem cells and overcoming drug resistance.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K